« Return to News | Clinical Intelligence

Genomic launches breast cancer trial

Wednesday, April 27, 2011 02:01 PM

Genomic Health has launched RxPONDER S1007, a breast cancer clinical trial being led by SWOG, one of the National Cancer Institute’s (NCI) cancer cooperative groups.  The trial is designed to determine the effect of chemotherapy in breast cancer patients with one to three positive nodes who have a Recurrence Score (RS) result equal to, or less than, 25 as determined by the Oncotype DX breast cancer test.

Researchers will utilize the Oncotype DX breast cancer test to quantify each patient's individual risk of recurrence in order to assign them to the appropriate treatment.  Women who have tumors with a RS result equal to, or less than, 25, the primary study group, will be randomized to receive hormonal therapy with or without chemotherapy.  Women who have tumors with a high RS, greater than 25, will be offered chemotherapy plus hormonal therapy as standard of care, or in the context of other clinical studies. 

While the trial is being led by SWOG, it is expected to be opened by the other major cooperative groups as well, giving patients wide access to the trial throughout the world.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.